(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 89.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Ac Immune Sa's revenue in 2024 is $16,819,318.On average, 2 Wall Street analysts forecast ACIU's revenue for 2024 to be $1,403,649,280, with the lowest ACIU revenue forecast at $1,125,895,359, and the highest ACIU revenue forecast at $1,681,403,202. On average, 3 Wall Street analysts forecast ACIU's revenue for 2025 to be $6,838,698,331, with the lowest ACIU revenue forecast at $2,678,341,383, and the highest ACIU revenue forecast at $14,955,064,700.
In 2026, ACIU is forecast to generate $11,153,803,893 in revenue, with the lowest revenue forecast at $3,197,146,029 and the highest revenue forecast at $19,110,461,757.